AI Article Synopsis
- The current diagnostic tests for latent tuberculosis infection (LTBI), such as the interferon-γ release assay (IGRA) and the tuberculin skin test (TST), have significant limitations, highlighting the need for more accurate and specific methods.
- This study aimed to evaluate the cost-effectiveness of the Cy-Tb test compared to the TST in diagnosing LTBI and preventing tuberculosis (TB) through preventive therapy.
- Results suggest that while the Cy-Tb test has an additional cost of approximately 18,658 Indian rupees (~$223.5) per additional LTBI case diagnosed, it is considered cost-effective and could be seen as a cost-saving option if its price is decreased.
Article Abstract
Background: Latent tuberculosis infection (LTBI) remains a significant challenge, as there is no gold standard diagnostic test. Current methods used for identifying LTBI are the interferon-γ release assay (IGRA), which is based on a blood test, and the tuberculin skin test (TST), which has low sensitivity. Both these tests are inadequate, primarily because they have limitations with the low bacterial burden characteristic of LTBI. This highlights the need for the development and adoption of more specific and accurate diagnostic tests to effectively identify LTBI. Herein we estimate the cost-effectiveness of the Cy-Tb test as compared with the TST for LTBI diagnosis.
Methods: An economic modelling study was conducted from a health system perspective using decision tree analysis, which is most widely used for cost-effectiveness analysis using transition probabilities. Our goal was to estimate the incremental cost and number of TB cases prevented from LTBI using the Cy-Tb diagnostic test along with TB preventive therapy (TPT). Secondary data such as demographic characteristics, treatment outcome, diagnostic test results and cost data for the TST and Cy-Tb tests were collected from the published literature. The incremental cost-effectiveness ratio was calculated for the Cy-Tb test as compared with the TST. The uncertainty in the model was evaluated using one-way sensitivity analysis and probability sensitivity analysis.
Results: The study findings indicate that for diagnosing an additional LTBI case with the Cy-Tb test and to prevent a TB case by providing TPT prophylaxis, an additional cost of 18 658 Indian rupees (US${\$}$223.5) is required. The probabilistic sensitivity analysis indicated that using the Cy-Tb test for diagnosing LTBI was cost-effective as compared with TST testing. If the cost of the Cy-Tb test is reduced, it becomes a cost-saving strategy.
Conclusions: The Cy-Tb test for diagnosing LTBI is cost-effective at the current price, and price negotiations could further change it into a cost-saving strategy. This finding emphasizes the need for healthcare providers and policymakers to consider implementing the Cy-Tb test to maximize economic benefits. Bulk procurements can also be considered to further reduce costs and increase savings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/inthealth/ihae048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of diagnostic technologies for mycobacterium tuberculosis infection in India and Brazil.
PLOS Glob Public Health
November 2024
Department of Infectious Disease and Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Article Synopsis
- The study evaluates the cost and effectiveness of new skin-based tests and blood-based assays for tuberculosis in high-burden countries like India and Brazil.
- Results show that Diaskintest is more cost-effective than the traditional PPD-tuberculin test (TST) for diagnosing TB, with costs of $22.6 in Brazil and $41.0 in India per correctly diagnosed case.
- While Diaskintest is cheaper, TSPOT.TB blood test is more effective despite its higher cost, with an incremental cost-effectiveness ratio of $74 in India and $55 in Brazil.
Systematic review of the economic impact of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection compared with tuberculin skin test and interferon-gamma release assays.
PLOS Glob Public Health
October 2024
Institute for Global Health, University College London, London, United Kingdom.
Article Synopsis
- The current tests for identifying TB infection include the Tuberculin Skin Test (TST) and interferon-gamma release assays (IGRA), but access and implementation issues limit their use.
- Novel skin tests such as Diaskintest and C-TST show potential for better scalability and accuracy, though evidence on their economic impact is still lacking.
- Systematic reviews indicated that while costs for TBST were generally lower than TST and IGRA, there is limited high-quality evidence for TBST, and the existing studies on TST and IGRA lean towards high-income settings without clear economic consensus.
Study protocol: diagnostic accuracy study comparing Cy-Tb and STANDARD F TB-Feron FIA tests for tuberculosis infection diagnosis in Vietnam.
BMJ Open
August 2024
Department of Medicine, Unit of Infectious Disease, Karolinska Institute, Stockholm, Sweden.
Article Synopsis
- The study focuses on evaluating two new diagnostic tests for tuberculosis (TB) infection, Cy-Tb and Standard F TB, which aim to improve accuracy and reduce costs in low-resource settings.
- It involves a cross-sectional trial with participants divided into three groups: those with confirmed TB, household contacts, and people without TB, comparing these tests with a standard reference test, QFT-Plus.
- Ethical approval has been obtained, and the research findings will be shared with the scientific community and policymakers through publications.
Article Synopsis
- The current diagnostic tests for latent tuberculosis infection (LTBI), such as the interferon-γ release assay (IGRA) and the tuberculin skin test (TST), have significant limitations, highlighting the need for more accurate and specific methods.
- This study aimed to evaluate the cost-effectiveness of the Cy-Tb test compared to the TST in diagnosing LTBI and preventing tuberculosis (TB) through preventive therapy.
- Results suggest that while the Cy-Tb test has an additional cost of approximately 18,658 Indian rupees (~$223.5) per additional LTBI case diagnosed, it is considered cost-effective and could be seen as a cost-saving option if its price is decreased.
Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.
EClinicalMedicine
February 2023
Institute for Global Health, University College London, London, United Kingdom.
Article Synopsis
- Scientists compared two tests (TST and IGRA) to see which one is better at predicting active tuberculosis (TB) disease.
- They looked at data from 13 studies with over 32,000 people to find out which test was more reliable.
- The IGRA test was found to be better in certain countries, especially where fewer people have TB.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!